Vancheswaran Gopalakrishnan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6560632/publications.pdf

Version: 2024-02-01

46	14,545	236925	265206
papers	citations	25 h-index	42 g-index

50	50	50	19474
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Gut microbiome modulates response to antiâ€“PD-1 immunotherapy in melanoma patients. Science, 2018, 359, 97-103.	12.6	3,126
2	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	27.8	1,421
3	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell, 2018, 175, 998-1013.e20.	28.9	1,260
4	The human tumor microbiome is composed of tumor typeâ€“specific intracellular bacteria. Science, 2020, 368, 973-980.	12.6	1,077
5	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science, 2017, 357, 1156-1160.	12.6	1,059
6	The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell, 2018, 33, 570-580.	16.8	911
7	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery, 2016, 6, 827-837.	9.4	785
8	The microbiome, cancer, and cancer therapy. Nature Medicine, 2019, 25, 377-388.	30.7	712
9	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine, 2017, 9, .	12.4	689
10	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine, 2018, 24, 1649-1654.	30.7	592
11	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature Medicine, 2018, 24, 1804-1808.	30.7	521
12	The gut microbiota influences anticancer immunosurveillance and general health. Nature Reviews Clinical Oncology, 2018, 15, 382-396.	27.6	389
13	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science, 2021, 374, 1632-1640.	12.6	369
14	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2018, 19, 181-193.	10.7	233
15	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine, 2021, 27, 1432-1441.	30.7	216
16	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery, 2017, 7, 1088-1097.	9.4	160
17	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Research, 2019, 29, 846-861.	12.0	160
18	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine, 2017, 2, .	3.8	120

#	Article	IF	Citations
19	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunology Research, 2019, 7, 1025-1035.	3.4	70
20	Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. Clinical Infectious Diseases, 2020, 71, 63-71.	5.8	61
21	The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. Trends in Immunology, 2018, 39, 900-920.	6.8	56
22	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology, 2016, 5, e1136044.	4.6	55
23	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. OncoImmunology, 2017, 6, e1321187.	4.6	45
24	Mitochondrial DNA Copy Number in Peripheral Blood and Melanoma Risk. PLoS ONE, 2015, 10, e0131649.	2.5	29
25	Adult versus Pediatric Neuroblastoma: The M.D. Anderson Cancer Center Experience. Sarcoma, 2014, 2014, 1-6.	1.3	27
26	Synovial Sarcoma of the Head and Neck: A Single Institution Review. Sarcoma, 2017, 2017, 1-8.	1.3	27
27	Interaction of molecular alterations with immune response in melanoma. Cancer, 2017, 123, 2130-2142.	4.1	24
28	Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy.. Journal of Clinical Oncology, 2017, 35, 3008-3008.	1.6	23
29	Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist, 2017, 22, 1271-1277.	3.7	20
30	Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. Frontiers in Immunology, 2018, 9, 946.	4.8	19
31	Linking Associations of Rare Low-Abundance Species to Their Environments by Association Networks. Frontiers in Microbiology, 2018, 9, 297.	3.5	19
32	Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). Neoplasia, 2022, 31, 100813.	5.3	14
33	Engraftment of Bacteria after Fecal Microbiota Transplantation Is Dependent on Both Frequency of Dosing and Duration of Preparative Antibiotic Regimen. Microorganisms, 2021, 9, 1399.	3.6	12
34	Prognosis of T1 synovial sarcoma depends upon surgery by oncologic surgeons. Journal of Surgical Oncology, 2016, 114, 490-494.	1.7	11
35	Intervention strategies for microbial therapeutics in cancer immunotherapy. Immuno-Oncology Technology, 2020, 6, 9-17.	0.3	8
36	Abstract 2672: Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome. , 2017, , .		4

#	Article	IF	Citations
37	Implicating or exonerating the gut microbiome in blood-borne infection. Nature Medicine, 2018, 24, 1788-1789.	30.7	3
38	The Gut and Cervical Microbiome Promote Immune Activation and Response to Chemoradiation in Cervical Cancer. SSRN Electronic Journal, 0, , .	0.4	3
39	Working with Human Tissues for Translational Cancer Research. Journal of Visualized Experiments, 2015, , .	0.3	2
40	Antibiotics and Immunotherapy: Too Much of Anything is Bad!. European Urology, 2020, 78, 544-545.	1.9	2
41	Survival of upper tract urothelial carcinoma: A population-based analysis.. Journal of Clinical Oncology, 2013, 31, 257-257.	1.6	1
42	Multidimensional spatial characterization of the tumor microenvironment (TME) in synchronous melanoma metastases (SMM) to yield insights into mixed responses to therapy in metastatic melanoma (MM) patients (pts).. Journal of Clinical Oncology, 2017, 35, 9575-9575.	1.6	1
43	Are adult and pediatric neuroblastoma clinically different entities?. Journal of Clinical Oncology, 2013, 31, 10049-10049.	1.6	0
44	A rapid method to estimate the value of genetic analysis of excised cancers: A comparison in the phase I setting.. Journal of Clinical Oncology, 2013, 31, 264-264.	1.6	0
45	Head and neck synovial sarcomas: Clinical characteristics and survival.. Journal of Clinical Oncology, 2016, 34, e22523-e22523.	1.6	0
46	Abstract 2392: Genomic and immune heterogeneity in synchronous melanoma metastases is associated with differential tumor growth and response to therapy. , 2016, , .		0